New registry tracks Real-World safety of diabetes device

NCT ID NCT07197775

ENROLLING_BY_INVITATION Knowledge-focused Sponsor: Endogenex, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This registry will follow 500 people with type 2 diabetes who have already been treated with the Endogenex System. The goal is to collect long-term safety data and see how the device performs in everyday use. Participants must agree to share their medical records and attend follow-up visits.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Endogenex System

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES DIABETES MELLITUS, TYPE 2 TYPE 2 DIABETES TYPE 2 DIABETES MELLITUS (T2DM) TYPE2DIABETES

Contacts and locations

Locations

Care Access

Quincy, Massachusetts, 02169, United States
Care Access

Raleigh, North Carolina, 27607, United States
Care Access

Houston, Texas, 77054, United States
St Vincent's Hospital Melbourne

Fitzroy, Victoria, 3065, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.